<p>A Vaccine Against Group B <em>Streptococcus</em>: Recent Advances</p>
نویسندگان
چکیده
منابع مشابه
Status of group B streptococcal vaccine development
Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies ...
متن کاملNovel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphatase fusions.
Using an alkaline phosphatase-based genetic screening method, we identified a number of proteins that are potentially located on the outer surface of Group B streptococcus (Streptococcus agalactiae). In an enzyme-linked immunosorbent assay, antisera raised against two of the proteins, the streptococcal yutD homologue and a subunit of an ABC transporter, recognised clinically important serotypes...
متن کاملAn oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
We have developed an oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. Purified group B streptococcal type III capsular polysaccharide was depolymerized by enzymatic digestion using endo-beta-galactosidase produced by Citrobacter freundii. Following enzymatic digestion, oligosaccharides were fractionated by gel filtration chromatography on Sephadex G-75. A...
متن کاملGroup B streptococcal epidemiology and vaccine needs in developed countries.
Development of a group B streptococcal vaccine (GBS) vaccine is the most promising approach for the prevention of GBS infections in babies, given the potential adverse effects of intrapartum antibiotic prophylaxis as well as the need for effective prevention of both adult and late perinatal disease. There are numerous prevention strategies at this time but none are 100% effective in the eradica...
متن کاملGonococcal Vaccine Development: Lessons from Group B Meningococcal Vaccines
A retrospective case-control study, published online in The Lancet on July 10, 2017, reported that MeNZB–a group B meningococcal vaccine– was effective for preventing gonorrhea acquisition. The vaccine was administered to about 1 million adolescents in New Zealand between 2004 and 2006, and gonorrhea cases fell 31% in those vaccinated compared to unvaccinated controls. The exact mechanisms by w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Infection and Drug Resistance
سال: 2020
ISSN: 1178-6973
DOI: 10.2147/idr.s203454